@entity1582 is the second most common @entity1583 . @entity2008 are important prognostic determinants that influence the clinical decision-making in @entity1582 ( @entity1582 ). @entity1 are considered high-risk if any of the following features are detected: hypodiploidy, deletion 13 by cytogenetics, t(4;14), t(14;16), t(14;20) and/or 17 p deletion. In the absence of these features @entity1 are considered standard risk. Outside of trials, risk-adapted therapy in the transplant-eligible high-risk @entity1 advocates use of @entity1749 -based induction therapy followed by autologous stem cell transplantation (ASCT) and @entity1749 -based maintenance therapy. High-risk, transplant-ineligible @entity1 should also utilize @entity1749 as initial therapy since it is known to overcome the poor prognosis associated with some high-risk features. The goal of therapy in high-risk @entity1 is to attain and maintain a state of complete remission as much as possible. In contrast, the standard-risk, transplant-eligible @entity1 may be treated with either @entity6985 - @entity619 or @entity1749 -based therapy followed by ASCT. In such @entity1 , ASCT can also be deferred until first relapse if the @entity1 are tolerating initial therapy well. @entity6985 maintenance therapy in the post-transplant setting in standard-risk @entity1 is controversial and not recommended routinely. For transplant-ineligible standard-risk @entity1 , multiple options exist, although in the absence direct comparisons, we prefer @entity6985 plus low-dose @entity619 over @entity3601 -based combinations. This review outlines evidence-based management approaches in @entity1582 , with a focus on risk-adapted therapy.

Update on risk stratification and treatment of newly diagnosed XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3601 :: ('MESH:D008558', 'Chemical') :: ['melphalan'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['newly-diagnosed multiple myeloma', 'NDMM', 'Multiple myeloma'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancy'] @entity6985 :: ('MESH:C467567', 'Chemical') :: ['Lenalidomide', 'lenalidomide'] @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['Chromosomal aberrations']
@entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']
